Press Release Sanofi-aventis
Sanofi Aventis: Study Shows Otamixaban
substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Paris, France - August 30, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced
today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42
percent the odds of the composite primary endpoint of death, myocardial infarction, urgent
revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard
UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the
SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of
Cardiology congress in Barcelona and simultaneously published online in The Lancet.
English pdf
French pdf
|
